Pain caused by damage or disease affecting the somatosensory nervous system, characterized by altered expression of voltage-gated ion channels (Nav1.8, Kv1.2), upregulation of inflammatory signals (PGE2, pro-inflammatory oxylipins), and reduced axon density in skin. Unlike nociceptive pain (tissue damage signals), neuropathic pain represents aberrant neuronal signaling independent of ongoing tissue injury, often persisting after healing and resistant to conventional analgesics.
Think of your nerve as a well-insulated electrical cable with controlled voltage gates that open and close on command. When a nerve is injured or diseased, it's like someone has rewired the cable with faulty switches that trigger randomly—the sodium gates (Nav1.8) get stuck in "hair-trigger" mode, firing at the slightest provocation or even spontaneously, while the potassium gates (Kv1.2) that normally shut down excessive firing get broken. Meanwhile, the insulation itself is fraying (reduced myelin), and inflammatory molecules like PGE2 are sprayed onto the cable like corrosive acid, further sensitizing the system. The result is like a car alarm that goes off every time a leaf touches it—or even when nothing touches it at all. To make matters worse, the early life "factory settings" of your pain system can be permanently altered if you experienced stress during critical developmental windows (like NICUs or maternal separation), leaving you with a lifelong hypersensitive alarm system. The dietary "fuel mix" matters too: feeding the system too much linoleic acid (ω-6) generates inflammatory oxidation products that keep spraying acid on the cables, while DHA (ω-3) acts like protective insulation repair.
Neuropathic pain arises from multiple converging pathological processes affecting peripheral and central pain pathways:
Ion Channel Dysregulation:
- Nerve injury → upregulation of Nav1.8 (TTX-resistant sodium channel) in dorsal root ganglia → increased spontaneous ectopic firing and reduced activation threshold
- Concurrent downregulation of Kv1.2 (voltage-gated potassium channel) → impaired repolarization → prolonged action potential duration → sustained neuronal firing
- Nav1.8:Kv1.2 ratio shift creates hyperexcitable state with spontaneous activity and mechanical allodynia
Inflammatory Cascade:
Neurotrophin Involvement:
- NGF upregulation in injured tissue → binding to TrkA Receptor on nociceptors → retrograde transport to dorsal root ganglion → transcriptional changes → increased Substance P and CGRP synthesis → enhanced pain signaling
- NGF → increased expression of TRPV1 channels → thermal and chemical hypersensitivity
Structural Changes:
- Small-fiber damage → reduced intraepidermal nerve fiber (IENF density) → diagnostic marker for small-fiber neuropathy
- Normal IENF density: >7.63 fibers/mm (distal leg); <5 fibers/mm indicates small-fiber loss
- ATF3 (activating transcription factor 3) expression in dorsal root ganglia → specific biomarker of active nerve injury
Central Sensitization Component:
graph TD
A[Nerve Injury/Dysfunction] --> B[Ion Channel Remodeling]
A --> C[Inflammatory Cascade]
A --> D[Neurotrophin Upregulation]
B --> B1["Nav1.8 ↑"]
B --> B2["Kv1.2 ↓"]
B1 --> E[Hyperexcitability]
B2 --> E
C --> C1[PLA2G7 activates]
C1 --> C2["Arachidonic acid → Oxylipins"]
C2 --> C3[PGE2 production]
C3 --> C4[EP receptor activation]
C4 --> C5[PKA phosphorylates Nav1.8]
C5 --> E
D --> D1["NGF ↑"]
D1 --> D2[TrkA activation]
D2 --> D3["Substance P & CGRP ↑"]
D3 --> E
E --> F[Spontaneous Pain & Allodynia]
E --> G[Central Sensitization]
G --> H[Chronic Neuropathic Pain]
I["High ω-6 Diet"] --> C2
J[DHA Supplementation] --> K[Compete with AA]
K --> L["↓ Oxylipins, ↑ SPMs"]
L --> M[Pain Resolution]
Early Life Programming:
- Early Life Stress (ELS) (maternal separation, NICUs exposure) → HPA-axis dysregulation → altered glucocorticoid-mediated immune regulation
- NICUs → elevated cortisol during critical development → permanent upregulation of pain pathway genes → lifelong hyperalgesia risk
- Epigenetic modifications (DNA methylation of pain-related genes) persist into adulthood
Neuropathic pain represents a distinct pain phenotype requiring different therapeutic approaches than nociceptive or inflammatory pain, as it involves primary nervous system dysfunction rather than tissue damage signaling.
Clinical Recognition:
- LANSS score (Leeds Assessment of Neuropathic Symptoms and Signs) and NPSI total score (Neuropathic Pain Symptom Inventory) provide validated screening tools
- Patients describe burning, shooting, electric-shock quality pain, often with allodynia (pain from non-painful stimuli) and spontaneous pain without clear triggers
- Common conditions: diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy, fibromyalgia (central neuropathic component)
Nutritional Intervention Strategy:
Selfish Systems Connection:
- Neuropathic pain exemplifies selfish immune system and Selfish Brain conflict: the immune system generates inflammatory mediators to protect against infection/injury, but these same mediators sensitize pain pathways, and the brain amplifies pain signals to enforce rest
- central sensitisation represents the brain's "selfish" prioritization of threat detection at the cost of quality of life
- cortisol resistance in chronic pain states → inability to down-regulate inflammatory pain mediators → self-perpetuating cycle
Metamodel Applications:
- Metamodel 0 (Evolutionary Mismatch): Modern high-linoleic acid diets (vegetable oils, processed foods) create unprecedented tissue ω-6 loading that ancestral pain systems weren't designed to handle
- Metamodel 1 (Chronic Stress): Early Life Stress (ELS) programs permanent pain amplification through epigenetic mechanisms
- Metamodel 3 (Barrier Dysfunction): leaky gut increases systemic inflammatory tone, contributing to neuroinflammation and pain sensitization
- Metamodel 5 (Metabolic Dysfunction): Insulin resistance alters pain processing; diabetic neuropathy represents the intersection of metabolic and neuropathic mechanisms
Intervention Implications:
- Address ω-6 overload: eliminate vegetable oils (corn, soybean, sunflower), increase wild-caught fish, algae-based DHA
- Consider darapladib (PLA2G7 inhibitor) to block inflammatory oxylipin production—though primarily cardiovascular drug, mechanism suggests neuropathic pain application
- Target NGF-TrkA Receptor pathway (emerging biologics)
- Reduce early-life adversity in next generation (prevention strategy)
- pain neuroscience education to reduce central amplification through understanding
- Address concurrent gut dysbiosis and intestinal permeability to reduce systemic inflammatory drive
Clinical Thresholds:
- IENF density <5 fibers/mm (distal leg) diagnostic for small-fiber neuropathy
- PGE2 >15 pg/mL in CSF associated with neuropathic pain states
- omega-3 index target >8% for anti-inflammatory effects (ratio of EPA+DHA to total fatty acids in red blood cell membranes)
- Nav1.8 sodium channel upregulation and Kv1.2 potassium channel downregulation create hyperexcitable state in damaged nerves
- ATF3 expression in dorsal root ganglia serves as specific molecular biomarker of active nerve injury
- IENF density <5 fibers/mm (distal leg biopsy) indicates small-fiber neuropathy—normal is >7.63 fibers/mm
- Early Life Stress (ELS) including NICUs exposure and maternal separation programs lifelong neuropathic pain vulnerability through epigenetic mechanisms
- ω-6:ω-3 ratio >15:1 in modern diets (ancestral ~1:1) drives pro-inflammatory oxylipin production via PLA2G7
- DHA 6 grams daily reverses neuropathic pain symptoms—Boyd 2021 showed superiority over conventional neuropathic pain pharmacotherapy in some patients
- linoleic acid (18:2 ω-6) → arachidonic acid (20:4 ω-6) → oxylipins cascade generates pro-nociceptive mediators
- PGE2 sensitizes nociceptors by phosphorylating Nav1.8 channels via PKA pathway
- NGF upregulation increases Substance P, CGRP, and TRPV1 expression, amplifying pain signaling
- Neuropathic pain persists independent of ongoing tissue damage—represents primary nervous system dysfunction, not secondary signaling
- ω-6 polyunsaturated fatty acids — linoleic acid and arachidonic acid are substrates for PLA2G7-mediated production of pro-inflammatory oxylipins that sensitize nociceptors and perpetuate neuropathic pain
- ω-3 polyunsaturated fatty acids — DHA and EPA compete with arachidonic acid for enzymatic conversion, reducing inflammatory oxylipins and generating specialized pro-resolving mediators (SPMs) that actively resolve neuroinflammation; 6g daily DHA shows clinical efficacy
- prostaglandin E2 — pro-inflammatory mediator elevated in neuropathic pain states that activates EP receptors on nociceptors, triggering PKA-mediated phosphorylation of Nav1.8 channels and increasing excitability
- NGF — upregulated in injured tissue and nerve, binds TrkA Receptor to increase Substance P, CGRP, and TRPV1 expression, amplifying pain transmission and maintaining sensitization
- dorsal root ganglion — primary site of pathological ion channel remodeling (Nav1.8↑, Kv1.2↓), ATF3 expression marking injury, and NGF-driven transcriptional changes in neuropathic pain
- Early Life Stress (ELS) — maternal separation and NICUs exposure program permanent pain pathway amplification through epigenetic modifications and HPA-axis dysregulation, increasing lifetime neuropathic pain risk
- small-fiber neuropathy — specific subtype characterized by loss of unmyelinated C-fibers and thinly myelinated A-delta fibers, diagnosed by reduced IENF density (<5 fibers/mm) and associated with burning pain and autonomic dysfunction
- Neurologic Pain Signature (NPS) — distinct brain activation pattern in neuropathic pain, different from nociceptive pain processing, involving altered activity in anterior cingulate cortex, insula, and somatosensory cortex
- central sensitisation — persistent peripheral neuropathic input drives increased dorsal horn excitability, expanding receptive fields and creating Secondary Hyperalgesia in adjacent uninjured tissue
- peripheral neuropathy — broader category encompassing neuropathic pain, including diabetic neuropathy (metabolic damage), chemotherapy-induced neuropathy (toxic damage), and compression neuropathies
- PLA2G7 — phospholipase A2 enzyme that cleaves arachidonic acid from membrane phospholipids, generating pro-inflammatory oxylipins; darapladib inhibitor shows potential for neuropathic pain intervention
- oxylipins — bioactive lipid metabolites of arachidonic acid (12-HETE, 15-HETE) that sensitize nociceptors, increase vascular permeability, and sustain neuroinflammation in neuropathic states
- linoleic acid — 18:2 ω-6 fatty acid abundant in modern vegetable oils, converted to arachidonic acid and stored in membrane phospholipids, serving as substrate for pro-nociceptive oxylipin synthesis
- arachidonic acid — 20:4 ω-6 fatty acid that serves as direct substrate for COX-2, 5-LOX, and 12-LOX enzymes generating PGE2 and inflammatory oxylipins central to neuropathic pain pathogenesis
- DHA — docosahexaenoic acid (22:6 ω-3) that competes with arachidonic acid for enzyme access, reduces inflammatory oxylipins, generates Resolvins and Protectins, and improves nerve membrane function; 6g daily clinically effective
- chronic pain — neuropathic pain represents major chronic pain subtype (30-40% of chronic pain patients), distinct from nociceptive and inflammatory mechanisms, requiring specialized diagnostic and treatment approaches
- fibromyalgia — centralized neuropathic pain syndrome with widespread hyperalgesia, central sensitisation, altered Neurologic Pain Signature (NPS), and often comorbid with small-fiber neuropathy (40-50% of fibromyalgia patients)
- inflammation — chronic neuroinflammation with PGE2, IL-1β, TNF-α, and oxylipins drives and maintains neuropathic pain; distinct from acute protective inflammation, represents maladaptive chronic state
- cortisol resistance — in chronic neuropathic pain, glucocorticoid receptor desensitization prevents normal anti-inflammatory regulation, sustaining inflammatory mediator production and pain amplification
- specialized pro-resolving mediators (SPMs) — DHA-derived Resolvins, Protectins, and Maresins actively resolve neuroinflammation, promote efferocytosis, and restore tissue homeostasis; deficiency in neuropathic pain states
- insulin resistance — metabolic dysfunction increases neuropathic pain risk through multiple mechanisms including increased AGEs, oxidative stress, microvascular dysfunction, and altered neurotrophic support; diabetic neuropathy most common neuropathic pain condition